Scholarlink

Background <p>Effective diagnostic tools for prompt identification of high-risk locally advanced cervical cancer (LACC) patients are needed to facilitate early, individualized treatment. The aim of this work was to assess temporal changes in tumor radiomics (delta radiomics) from T2-weighted imaging (T2WI) during concurrent chemoradiotherapy (CCRT) in LACC patients, and their association with progression-free survival (PFS). Furthermore, to develop, validate, and compare delta- and pretreatment radiomic signatures for prognostic modeling.</p> Methods <p>A total of 110 LACC patients undergoing CCRT with MRI at baseline and mid-treatment were divided into training (cohort<sub>T</sub>: <i>n</i> = 73) and validation (cohort<sub>V</sub>: <i>n</i> = 37) cohorts. Radiomic features were extracted from tumors segmented on pre-CCRT and mid-CCRT T2WI and radiomic deltas (delta features) were computed. Two radiomic signatures for predicting PFS were constructed by least absolute shrinkage and selection operator (LASSO) Cox regression: Delta<sub>rad</sub> (from delta features) and Pre-CCRT<sub>rad</sub> (from pre-CCRT features). Prognostic performance of the radiomic signatures, 2018 International Federation of Gynecology and Obstetrics (FIGO) stage (I–IV), and baseline MRI-derived maximum tumor diameter (Tumor<sub>max</sub>: ≤2&#xa0;cm; &gt;2 and ≤ 4&#xa0;cm; &gt;4&#xa0;cm) was evaluated by area under time-dependent receiver operating characteristics (tdROC) curves (AUC) in cohort<sub>T</sub> and cohort<sub>V</sub> (AUC<sub>T</sub>/AUC<sub>V</sub>). Mann–Whitney U tests assessed differences in radiomic delta features. PFS was evaluated using the Kaplan–Meier method with log-rank tests.</p> Results <p>Delta<sub>rad</sub> (AUC<sub>T</sub>/AUC<sub>V</sub>: 0.74/0.79) marginally outperformed Pre-CCRT<sub>rad</sub> (0.72/0.75) for predicting 5-year PFS, and both signatures clearly surpassed that of FIGO (0.61/0.61) and Tumor<sub>max</sub> (0.58/0.65). In total, four features within Delta<sub>rad</sub> and Pre-CCRT<sub>rad</sub> significantly differed in delta feature values between progressors and non-progressors, being consistently lower in progressors (<i>p</i> ≤ 0.03 for all). High Delta<sub>rad</sub> and Pre-CCRT<sub>rad</sub> radiomic scores were associated with poor PFS (<i>p</i> ≤ 0.04 for Delta<sub>rad</sub> in cohort<sub>T</sub>/Pre-CCRT<sub>rad</sub> in both cohorts; <i>p</i> = 0.11 for Delta<sub>rad</sub> in cohort<sub>V</sub>).</p> Conclusions <p>Delta- and pretreatment radiomic signatures equally allow early prognostication in LACC, outperforming FIGO stage and MRI-assessed maximum tumor diameter.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

MRI delta radiomics during chemoradiotherapy for prognostication in locally advanced cervical cancer

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年1月22日

查看全文
  • Kari S. Wagner-Larsen,
  • Njål Lura,
  • Ankush Gulati,
  • Stian Ryste,
  • Erlend Hodneland,
  • Kristine E. Fasmer,
  • Kathrine Woie,
  • Bjørn I. Bertelsen,
  • Øyvind Salvesen,
  • Mari K. Halle,
  • Noeska Smit,
  • Camilla Krakstad,
  • Ingfrid S. Haldorsen

摘要

Background

Effective diagnostic tools for prompt identification of high-risk locally advanced cervical cancer (LACC) patients are needed to facilitate early, individualized treatment. The aim of this work was to assess temporal changes in tumor radiomics (delta radiomics) from T2-weighted imaging (T2WI) during concurrent chemoradiotherapy (CCRT) in LACC patients, and their association with progression-free survival (PFS). Furthermore, to develop, validate, and compare delta- and pretreatment radiomic signatures for prognostic modeling.

Methods

A total of 110 LACC patients undergoing CCRT with MRI at baseline and mid-treatment were divided into training (cohortT: n = 73) and validation (cohortV: n = 37) cohorts. Radiomic features were extracted from tumors segmented on pre-CCRT and mid-CCRT T2WI and radiomic deltas (delta features) were computed. Two radiomic signatures for predicting PFS were constructed by least absolute shrinkage and selection operator (LASSO) Cox regression: Deltarad (from delta features) and Pre-CCRTrad (from pre-CCRT features). Prognostic performance of the radiomic signatures, 2018 International Federation of Gynecology and Obstetrics (FIGO) stage (I–IV), and baseline MRI-derived maximum tumor diameter (Tumormax: ≤2 cm; >2 and ≤ 4 cm; >4 cm) was evaluated by area under time-dependent receiver operating characteristics (tdROC) curves (AUC) in cohortT and cohortV (AUCT/AUCV). Mann–Whitney U tests assessed differences in radiomic delta features. PFS was evaluated using the Kaplan–Meier method with log-rank tests.

Results

Deltarad (AUCT/AUCV: 0.74/0.79) marginally outperformed Pre-CCRTrad (0.72/0.75) for predicting 5-year PFS, and both signatures clearly surpassed that of FIGO (0.61/0.61) and Tumormax (0.58/0.65). In total, four features within Deltarad and Pre-CCRTrad significantly differed in delta feature values between progressors and non-progressors, being consistently lower in progressors (p ≤ 0.03 for all). High Deltarad and Pre-CCRTrad radiomic scores were associated with poor PFS (p ≤ 0.04 for Deltarad in cohortT/Pre-CCRTrad in both cohorts; p = 0.11 for Deltarad in cohortV).

Conclusions

Delta- and pretreatment radiomic signatures equally allow early prognostication in LACC, outperforming FIGO stage and MRI-assessed maximum tumor diameter.